Back to Resource Hub Article

The Changing Face of Oncology Endpoint Monitoring

Historically, endpoints in oncology clinical trials centered on tumor response, but this approach alone fails to take into account how well a treatment is tolerated or how patients cope with their symptoms.

More recently, industry and regulatory bodies increasingly incorporate patient-reported outcomes to measure soft endpoints.

In this article, we explore the value of PROs to clinical trials and outline important considerations for incorporating them into oncology trials.

Similar posts

Looking for more insights? Explore related resources.

BLOG POST

Lack of Uptake by Sponsors of the FDA Draft Recommendations for PROs in Oncology

VISIT THE BLOG
WEBINAR

Unleashing the Power of PROs Throughout Oncology Drug Development

WATCH THE WEBINAR
BROCHURE

Signant Health Corporate Overview

SEE THE BROCHURE

Get notified on new marketing insights

Here mention the benefits of subscribing